Overview of the Supreme Court’s review of skinny labeling in Amarin Inc. v. Hikma Pharm. USA, Inc., and its implications for generic drug makers, marketing, and inducement liability.
| less than a minute read
The Skinny Labeling Saga Continues

/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-22-14-15-25-334-6a1064fd1a1fd2238dcdffd6.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-22-14-13-14-735-6a10647a1a1fd2238dcdfd49.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-22-14-12-01-163-6a1064311a1fd2238dcdfbfd.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-05-22-14-09-56-202-6a1063b41a1fd2238dcdf984.jpg)